Further, since aberrant c-MYC activation/mutations have been associated with many cancer types [4, 5], hence in addition to prostate and liver cancers, the detection of AR-V7 in other human cancers, such as breast, bladder, and ovarian cancers (Supplementary Fig. 1B), suggests the existence of potential AR-V7 exacerbation on c-MYC oncogenesis in these AR-V7-positive tumors. This evidence concerns the gene AR and ovarian cancer.